FibroGen - FGEN Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FGEN, but not buy additional shares or sell existing shares.
View FGEN analyst ratings or view top-rated stocks.

5 brokers have issued 12-month price objectives for FibroGen's shares. Their FGEN share price forecasts range from $14.00 to $35.00. On average, they predict the company's stock price to reach $23.40 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price.
View analysts price targets for FGEN or view top-rated stocks among Wall Street analysts.

FibroGen's stock was trading at $16.02 at the beginning of 2023. Since then, FGEN stock has increased by 21.2% and is now trading at $19.41.
View the best growth stocks for 2023 here.

FibroGen saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 4,020,000 shares, a decline of 11.3% from the February 13th total of 4,530,000 shares. Based on an average daily trading volume, of 909,400 shares, the short-interest ratio is presently 4.4 days. Currently, 4.6% of the shares of the stock are short sold.
View FibroGen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our FGEN earnings forecast.

FibroGen, Inc. (NASDAQ:FGEN) issued its earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.25. The biopharmaceutical company earned $34.40 million during the quarter, compared to analysts' expectations of $23.95 million. FibroGen had a negative net margin of 208.66% and a negative trailing twelve-month return on equity of 338.94%. The company's revenue for the quarter was up 108.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.45) EPS.

ETFs with the largest weight of FibroGen (NASDAQ:FGEN) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Global X Aging Population ETF (AGNG) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.11%), First Trust Advisors LP (3.17%), Schroder Investment Management Group (1.87%), Geode Capital Management LLC (1.76%), Price T Rowe Associates Inc. MD (0.99%) and Eagle Asset Management Inc. (0.96%). Insiders that own company stock include Christine Chung, Enrique A Conterno, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FGEN stock can currently be purchased for approximately $19.41.

FibroGen (NASDAQ:FGEN) has a market capitalization of $1.83 billion and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.

The company employs 566 workers across the globe.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.